1. Home
  2. ALLT vs AKBA Comparison

ALLT vs AKBA Comparison

Compare ALLT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

N/A

Current Price

$7.47

Market Cap

381.1M

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.99

Market Cap

343.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALLT
AKBA
Founded
1996
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
381.1M
343.4M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
ALLT
AKBA
Price
$7.47
$0.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$12.40
$4.67
AVG Volume (30 Days)
251.8K
8.4M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.84
N/A
Revenue Next Year
$12.09
N/A
P/E Ratio
$469.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.12
$0.81
52 Week High
$11.92
$3.19

Technical Indicators

Market Signals
Indicator
ALLT
AKBA
Relative Strength Index (RSI) 43.82 49.90
Support Level $7.37 $0.82
Resistance Level $7.62 $1.52
Average True Range (ATR) 0.24 0.05
MACD -0.01 0.02
Stochastic Oscillator 19.51 91.63

Price Performance

Historical Comparison
ALLT
AKBA

About ALLT Allot Ltd.

Allot Ltd is a provider of security and network intelligence solutions for mobile, fixed, and cloud service providers, as well as enterprises. It offers network-based security solutions such as mobile security, DDoS protection, and IoT security, along with network analytics and traffic management. It focuses on expanding its Security-as-a-Service (SECaaS) offerings through the Allot Secure product family, which delivers unified protection for consumers and SMBs across mobile, fixed, and 5G networks. Its Allot Smart solutions enable service providers to analyze and manage network data, optimize performance, reduce costs, and enhance user experience. It has a customer base in Europe, which generates maximum revenue, as well as in Asia and Oceania, the Americas, the Middle East, and Africa.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: